Domů › Rakovina prsu › Nebraska › Omaha
Klinické studie Rakovina prsu v Omaha, NE
22 studií pro Rakovina prsu hledá účastníky v lokalitách v Omaha a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Probíhá náborFáze 3
- Nebraska Cancer Specialists, Omaha
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Probíhá náborFáze 3
- Research Site, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Probíhá náborFáze 2
- Nebraska Cancer Specialists, Omaha
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Probíhá náborFáze 2
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Probíhá náborFáze 3
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Probíhá náborFáze 1/2
- Nebraska Cancer Specialists, Omaha
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Probíhá náborFáze 3
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
- University of Nebraska Medical Center, Omaha
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Probíhá náborFáze 3
- Nebraska Cancer Specialists, Omaha
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Probíhá náborFáze 3
- Nebraska Cancer Specialists, Omaha
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Probíhá náborFáze 3
- Nebraska Medicine-Village Pointe, Omaha
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- a dalších 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Probíhá náborFáze 3
- Nebraska Cancer Specialists, Omaha
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Probíhá náborFáze 1
- Nebraska Cancer Specialists, Omaha
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Probíhá náborFáze 3
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Probíhá náborFáze 2
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Integrated Cancer Repository for Cancer Research
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- a dalších 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Probíhá náborFáze 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
ERAS Protocols in Breast Conserving Surgery
Probíhá nábor
- University of Nebraska Medical Center, Omaha
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Probíhá náborFáze 3
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · Vzdálenost 9 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Omaha
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Probíhá náborFáze 1
- Biotheryx Investigative Site, Omaha
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Probíhá náborObservační studie
- Nebraska Methodist, Omaha
Studie Rakovina prsu v jiných městech
- New York City, NY134 studií
- Houston, TX126 studií
- Boston, MA111 studií
- Nashville, TN80 studií
- Los Angeles, CA72 studií
- Edison, NJ68 studií
- St. Louis, MO64 studií
- Durham, NC63 studií
- Queens, NY63 studií
- Chicago, IL58 studií
- Philadelphia, PA56 studií
- Dallas, TX55 studií
Další studie v Omaha
- Rakovina prostaty27 studií
- Nemalobuněčný plicní karcinom24 studií
- Kolorektální karcinom18 studií
- Rakovina (všechny typy)18 studií
- Mnohočetný myelom16 studií
- Non-Hodgkinův lymfom14 studií
- Rakovina vaječníků14 studií
- Rakovina slinivky břišní14 studií
- Squamózní buněčný karcinom hlavy a krku13 studií
- Srdeční selhání13 studií
- Metastatický karcinom13 studií
- Rakovina ledvin (renální buněčný karcinom)12 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.